$14.99 $0.24 per serving
Product analysis
Boswellia 307 mg is aimed at joint comfort, with limited support from small trials of particular extracts. Its extract is not identified as one of those preparations, so the same benefit cannot be assumed.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality36
Boswellia is described by its plant compounds, but its quality remains uncertain. The unspecified carbohydrate form leaves another detail unclear.
Ingredient Transparency81
Amounts are stated, helping compare serving quantities. The boswellia description is provided, while the carbohydrate form remains unspecified.
Value For Money40
Value for money remains uncertain. The available cost information does not establish how the boswellia serving compares with alternatives.
Customer Satisfaction83
Customer ratings are strongly favorable across a substantial number of reviews. They describe satisfaction rather than establish health benefits.
Product Focus62
Boswellia has limited support for joint comfort from small, short trials of particular extracts. The different preparation here limits confidence that those benefits apply.
- Format
Tablet - Container
- 60 Tablet(s)
- Per serving
- $0.24
- Customer rating
- 4.6 · 2,274 ratings
Goals
Impact
Moderate effect
Boswellia · 307 mg
Boswellia at 307 mg is relevant to joint comfort through inflammation-related processes. Small, short studies suggest symptom support for particular preparations, but the ingredient here is not identified as the studied preparation, limiting how directly those findings apply.
How this product is rated for Joint Health
Ingredient fit97
The relevant ingredients are a clear focus of the formula. The assessed amounts fully meet the saved comparison benchmarks.
Goal fit
The relevant ingredients are a clear focus of the formula.
Dose adequacy
The assessed amounts fully meet the saved comparison benchmarks.
Pathways40
The strongest assessed area is inflammation control, with substantial coverage. One assessed area reaches the threshold for substantial coverage.
Depth
The strongest assessed area is inflammation control, with substantial coverage.
Breadth
One assessed area reaches the threshold for substantial coverage.
Evidence30
Boswellia provides the strongest evidence contribution among the assessed ingredients, with important limits on specific joint-comfort benefits. The assessed ingredients do not match the recognized trial preparations.
Evidence strength
Boswellia provides the strongest evidence contribution among the assessed ingredients, with important limits on specific joint-comfort benefits.
Studied preparation
The assessed ingredients do not match the recognized trial preparations.
Formulation logic100
The assessed ingredients can contribute independently or have their required partner. No configured ingredient conflict was matched in the supplied assessment. All ingredients included in this check reach its minimum amount threshold.
Partner coverage
The assessed ingredients can contribute independently or have their required partner.
Conflicts
No configured ingredient conflict was matched in the supplied assessment.
Effective doses
All ingredients included in this check reach its minimum amount threshold.
Impact
High effect
Boswellia · 307 mg
Boswellia has improved knee osteoarthritis symptoms in small studies of specific extracts. This product declares 307 mg of generic gum resin extract per serving, which does not establish equivalence to the studied 5-Loxin or Aflapin preparations. The symptom findings do not establish routine systemic anti-inflammatory benefit.
How this product is rated for Inflammation
Ingredient fit94
Boswellia provide the relevant ingredient findings. Amounts and the wider formula determine the degree of alignment.
Goal fit
The relevant ingredient is the main focus, although it is also associated with other goals.
Dose adequacy
The relevant amounts provide partial alignment with the saved reference amounts, with some below the studied exposure.
Pathways18
The main connection is through inflammatory enzyme pathways. No pathway reaches the saved coverage threshold at this serving.
Depth
The strongest finding concerns inflammatory enzyme pathways, with limited coverage at this serving.
Breadth
No pathway reaches the saved coverage threshold at this serving.
Evidence35
Boswellia leads the evidence finding. Preparation uncertainty limits Boswellia.
Evidence strength
Boswellia provides the leading evidence finding; the supported outcomes and populations limit how broadly it applies.
Studied preparation
Boswellia is not established as the preparation used in the reviewed trials.
Formulation logic100
The relevant ingredients have no unmet partner requirement or configured conflict. Their amount thresholds do not establish clinical benefit.
Partner coverage
The relevant ingredients have no unmet partner requirement in the supplied findings.
Conflicts
No configured ingredient conflict was identified in the supplied findings.
Effective doses
The ingredients counted here clear the saved amount threshold; that threshold does not prove an effective dose for every user.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Total Carbohydrates | 1 Gram(s) | |
Boswellia serrata gum resin extract (Boswellic Acids) | 307 mg |
Boswellia (Boswellic Acids) · 307 mg OverallScore85
Each serving lists 307 mg of Boswellia serrata gum resin extract. The recorded boswellic acid content is 40% for this source; the claim is not independently verified.
How this ingredient is rated
Composition and Label Disclosure70
The recorded boswellic acid content is 40% for this source; the claim is not independently verified.
Marker and Preparation Disclosure
The recorded boswellic acid content is 40% for this source; the claim is not independently verified.
Composition and Label Disclosure100
Each serving lists 307 mg of Boswellia serrata gum resin extract. The recorded boswellic acid content is 40% for this source; the claim is not independently verified.
Boswellia Amount and Marker Disclosure
Both the 307 mg serving amount and the 40% boswellic acid claim are recorded for this source.
Commercial Price and Usability
Price is not evaluated for this ingredient.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study.
- A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee.
- Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer's Disease.
- A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study.
- A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial.
- Oral herbal therapies for treating osteoarthritis.
- Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study.
- A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.